Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 77 entries
Sorted by: Best Match Show Resources per page
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.

RMD open

Braun J, Baraliakos X, Hermann KG, Landewé R, Machado PM, Maksymowych WP, Davies O, Hoepken B, Nurminen T, Stach C, van der Heijde D.
PMID: 28848654
RMD Open. 2017 Apr 24;3(1):e000430. doi: 10.1136/rmdopen-2017-000430. eCollection 2017.

OBJECTIVE: To report MRI outcomes and explore the relationship between clinical remission and MRI inflammation in patients with axial spondyloarthritis (axSpA) from the RAPID-axSpA trial, including radiographic (r-)axSpA and non-radiographic (nr-)axSpA.METHODS: RAPID-axSpA (NCT01087762) was double-blind and placebo-controlled to week...

Cite
Braun J, Baraliakos X, Hermann KG, et al. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 2017;3(1):e000430doi: 10.1136/rmdopen-2017-000430.
Braun, J., Baraliakos, X., Hermann, K. G., Landewé, R., Machado, P. M., Maksymowych, W. P., Davies, O., Hoepken, B., Nurminen, T., Stach, C., & van der Heijde, D. (2017). Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD open, 3(1), e000430. https://doi.org/10.1136/rmdopen-2017-000430
Braun, Jürgen, et al. "Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis." RMD open vol. 3,1 (2017): e000430. doi: https://doi.org/10.1136/rmdopen-2017-000430
Braun J, Baraliakos X, Hermann KG, Landewé R, Machado PM, Maksymowych WP, Davies O, Hoepken B, Nurminen T, Stach C, van der Heijde D. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 2017 Apr 24;3(1):e000430. doi: 10.1136/rmdopen-2017-000430. eCollection 2017. PMID: 28848654; PMCID: PMC5566980.
Copy Download .nbib Format: NLM
Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M .

Annals of the rheumatic diseases

Andreica I, Kiefer D, Rezniczek GA, Jast R, Buehring B, Kiltz U, Baraliakos X, Braun J.
PMID: 32732243
Ann Rheum Dis. 2020 Jul 30; doi: 10.1136/annrheumdis-2020-218609. Epub 2020 Jul 30.

No abstract available.

Cite
Andreica I, Kiefer D, Rezniczek GA, et al. Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218609.
Andreica, I., Kiefer, D., Rezniczek, G. A., Jast, R., Buehring, B., Kiltz, U., Baraliakos, X., & Braun, J. (2020). Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218609
Andreica, Ioana, et al. "Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218609
Andreica I, Kiefer D, Rezniczek GA, Jast R, Buehring B, Kiltz U, Baraliakos X, Braun J. Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M . Ann Rheum Dis. 2020 Jul 30; doi: 10.1136/annrheumdis-2020-218609. Epub 2020 Jul 30. PMID: 32732243.
Copy Download .nbib Format: NLM
[No title available]

Zeitschrift fur Rheumatologie

Braun J, Kiltz U, Baraliakos X.
PMID: 34251511
Z Rheumatol. 2021 Jul 12; doi: 10.1007/s00393-021-01048-6. Epub 2021 Jul 12.

No abstract available.

Cite
Braun J, Kiltz U, Baraliakos X. Erratum zu: „Verankerung“ von Klassifikationskriterien für axiale Spondyloarthritis – wie weit ist gut für die Diagnosestellung? . Z Rheumatol. 2021;doi: 10.1007/s00393-021-01048-6.
Braun, J., Kiltz, U., & Baraliakos, X. (2021). Erratum zu: „Verankerung“ von Klassifikationskriterien für axiale Spondyloarthritis – wie weit ist gut für die Diagnosestellung? . Zeitschrift fur Rheumatologie, . https://doi.org/10.1007/s00393-021-01048-6
Braun, J, et al. "Erratum zu: „Verankerung“ von Klassifikationskriterien für axiale Spondyloarthritis – wie weit ist gut für die Diagnosestellung?" . Zeitschrift fur Rheumatologie vol. (2021). doi: https://doi.org/10.1007/s00393-021-01048-6
Braun J, Kiltz U, Baraliakos X. Erratum zu: „Verankerung“ von Klassifikationskriterien für axiale Spondyloarthritis – wie weit ist gut für die Diagnosestellung? . Z Rheumatol. 2021 Jul 12; doi: 10.1007/s00393-021-01048-6. Epub 2021 Jul 12. German. PMID: 34251511.
Copy Download .nbib Format: NLM
Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version.

Zeitschrift fur Rheumatologie

Pfeil A, Krusche M, Vossen D, Berliner MN, Keyßer G, Krause A, Lorenz HM, Manger B, Schuch F, Specker C, Wollenhaupt J, Baraliakos X, Fleck M, Proft F.
PMID: 34605981
Z Rheumatol. 2021 Dec;80:64-67. doi: 10.1007/s00393-021-01080-6. Epub 2021 Oct 04.

No abstract available.

Cite
Pfeil A, Krusche M, Vossen D, et al. Mustercurriculum der Deutschen Gesellschaft für Rheumatologie für die Weiterbildung im Fachgebiet Innere Medizin und Rheumatologie. Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version. Z Rheumatol. 2021;80:64-67doi: 10.1007/s00393-021-01080-6.
Pfeil, A., Krusche, M., Vossen, D., Berliner, M. N., Keyßer, G., Krause, A., Lorenz, H. M., Manger, B., Schuch, F., Specker, C., Wollenhaupt, J., Baraliakos, X., Fleck, M., & Proft, F. (2021). Mustercurriculum der Deutschen Gesellschaft für Rheumatologie für die Weiterbildung im Fachgebiet Innere Medizin und Rheumatologie. Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version. Zeitschrift fur Rheumatologie, 8064-67. https://doi.org/10.1007/s00393-021-01080-6
Pfeil, Alexander, et al. "Mustercurriculum der Deutschen Gesellschaft für Rheumatologie für die Weiterbildung im Fachgebiet Innere Medizin und Rheumatologie." Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version. Zeitschrift fur Rheumatologie vol. 80 (2021): 64-67. doi: https://doi.org/10.1007/s00393-021-01080-6
Pfeil A, Krusche M, Vossen D, Berliner MN, Keyßer G, Krause A, Lorenz HM, Manger B, Schuch F, Specker C, Wollenhaupt J, Baraliakos X, Fleck M, Proft F. Mustercurriculum der Deutschen Gesellschaft für Rheumatologie für die Weiterbildung im Fachgebiet Innere Medizin und Rheumatologie. Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version. Z Rheumatol. 2021 Dec;80:64-67. doi: 10.1007/s00393-021-01080-6. Epub 2021 Oct 04. PMID: 34605981.
Copy Download .nbib Format: NLM
The ASAS-OMERACT core domain set for axial spondyloarthritis.

Seminars in arthritis and rheumatism

Navarro-Compán V, Boel A, Boonen A, Mease P, Landewé R, Kiltz U, Dougados M, Baraliakos X, Bautista-Molano W, Carlier H, Chiowchanwisawakit P, Dagfinrud H, de Peyrecave N, El-Zorkany B, Fallon L, Gaffney K, Garrido-Cumbrera M, Gensler LS, Haroon N, Kwan YH, Machado PM, Maksymowych WP, Poddubnyy D, Protopopov M, Ramiro S, Shea B, Song IH, van Weely S, van der Heijde D.
PMID: 34489113
Semin Arthritis Rheum. 2021 Aug 01; doi: 10.1016/j.semarthrit.2021.07.021. Epub 2021 Aug 01.

BACKGROUND: The current core outcome set for ankylosing spondylitis (AS) has had only minor adaptations since its development 20 years ago. Considering the significant advances in this field during the preceding decades, an update of this core set is...

Cite
Navarro-Compán V, Boel A, Boonen A, et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum. 2021;doi: 10.1016/j.semarthrit.2021.07.021.
Navarro-Compán, V., Boel, A., Boonen, A., Mease, P., Landewé, R., Kiltz, U., Dougados, M., Baraliakos, X., Bautista-Molano, W., Carlier, H., Chiowchanwisawakit, P., Dagfinrud, H., de Peyrecave, N., El-Zorkany, B., Fallon, L., Gaffney, K., Garrido-Cumbrera, M., Gensler, L. S., Haroon, N., Kwan, Y. H., Machado, P. M., Maksymowych, W. P., Poddubnyy, D., Protopopov, M., Ramiro, S., Shea, B., Song, I. H., van Weely, S., & van der Heijde, D. (2021). The ASAS-OMERACT core domain set for axial spondyloarthritis. Seminars in arthritis and rheumatism, . https://doi.org/10.1016/j.semarthrit.2021.07.021
Navarro-Compán, V, et al. "The ASAS-OMERACT core domain set for axial spondyloarthritis." Seminars in arthritis and rheumatism vol. (2021). doi: https://doi.org/10.1016/j.semarthrit.2021.07.021
Navarro-Compán V, Boel A, Boonen A, Mease P, Landewé R, Kiltz U, Dougados M, Baraliakos X, Bautista-Molano W, Carlier H, Chiowchanwisawakit P, Dagfinrud H, de Peyrecave N, El-Zorkany B, Fallon L, Gaffney K, Garrido-Cumbrera M, Gensler LS, Haroon N, Kwan YH, Machado PM, Maksymowych WP, Poddubnyy D, Protopopov M, Ramiro S, Shea B, Song IH, van Weely S, van der Heijde D. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum. 2021 Aug 01; doi: 10.1016/j.semarthrit.2021.07.021. Epub 2021 Aug 01. PMID: 34489113.
Copy Download .nbib Format: NLM
Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey.

Frontiers in medicine

Carubbi F, Bosch P, Machado PM, Scirè CA, Alunno A, Proft F, Baraliakos X, Dejaco C.
PMID: 34881271
Front Med (Lausanne). 2021 Nov 22;8:779975. doi: 10.3389/fmed.2021.779975. eCollection 2021.

No abstract available.

Cite
Carubbi F, Bosch P, Machado PM, et al. Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey. Front Med (Lausanne). 2021;8:779975doi: 10.3389/fmed.2021.779975.
Carubbi, F., Bosch, P., Machado, P. M., Scirè, C. A., Alunno, A., Proft, F., Baraliakos, X., & Dejaco, C. (2021). Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey. Frontiers in medicine, 8779975. https://doi.org/10.3389/fmed.2021.779975
Carubbi, Francesco, et al. "Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey." Frontiers in medicine vol. 8 (2021): 779975. doi: https://doi.org/10.3389/fmed.2021.779975
Carubbi F, Bosch P, Machado PM, Scirè CA, Alunno A, Proft F, Baraliakos X, Dejaco C. Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey. Front Med (Lausanne). 2021 Nov 22;8:779975. doi: 10.3389/fmed.2021.779975. eCollection 2021. PMID: 34881271; PMCID: PMC8645558.
Copy Download .nbib Format: NLM
Response to: 'Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years' by Parperis.

Annals of the rheumatic diseases

Baraliakos X, Richter A, Schmidt CO, Braun J.
PMID: 31900303
Ann Rheum Dis. 2022 Jan;81(1):e8. doi: 10.1136/annrheumdis-2019-216798. Epub 2020 Jan 03.

No abstract available.

Cite
Baraliakos X, Richter A, Schmidt CO, et al. Response to: 'Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years' by Parperis. Ann Rheum Dis. 2020;81(1):e8doi: 10.1136/annrheumdis-2019-216798.
Baraliakos, X., Richter, A., Schmidt, C. O., & Braun, J. (2022). Response to: 'Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years' by Parperis. Annals of the rheumatic diseases, 81(1), e8. https://doi.org/10.1136/annrheumdis-2019-216798
Baraliakos, Xenofon, et al. "Response to: 'Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years' by Parperis." Annals of the rheumatic diseases vol. 81,1 (2022): e8. doi: https://doi.org/10.1136/annrheumdis-2019-216798
Baraliakos X, Richter A, Schmidt CO, Braun J. Response to: 'Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years' by Parperis. Ann Rheum Dis. 2022 Jan;81(1):e8. doi: 10.1136/annrheumdis-2019-216798. Epub 2020 Jan 03. PMID: 31900303.
Copy Download .nbib Format: NLM
Successful Evaluation of Spinal Mobility Measurements With the Epionics SPINE Device in Patients With Axial Spondyloarthritis Compared to Controls.

The Journal of rheumatology

Kiefer D, Baraliakos X, Adolf D, Chatzistefanidi V, Schwarze I, Lange U, Brandt-Jürgens J, Stemmler E, Sartingen S, Braun J.
PMID: 34393107
J Rheumatol. 2022 Jan;49(1):44-52. doi: 10.3899/jrheum.201470. Epub 2021 Aug 15.

OBJECTIVE: Epionics SPINE (ES), a novel device that measures spinal movements using electronic sensors including range of motion (RoM) and speed (range of kinematics [RoK]), has already been validated in patients with mechanical back pain and healthy individuals. This...

Cite
Kiefer D, Baraliakos X, Adolf D, et al. Successful Evaluation of Spinal Mobility Measurements With the Epionics SPINE Device in Patients With Axial Spondyloarthritis Compared to Controls. J Rheumatol. 2021;49(1):44-52doi: 10.3899/jrheum.201470.
Kiefer, D., Baraliakos, X., Adolf, D., Chatzistefanidi, V., Schwarze, I., Lange, U., Brandt-Jürgens, J., Stemmler, E., Sartingen, S., & Braun, J. (2022). Successful Evaluation of Spinal Mobility Measurements With the Epionics SPINE Device in Patients With Axial Spondyloarthritis Compared to Controls. The Journal of rheumatology, 49(1), 44-52. https://doi.org/10.3899/jrheum.201470
Kiefer, David, et al. "Successful Evaluation of Spinal Mobility Measurements With the Epionics SPINE Device in Patients With Axial Spondyloarthritis Compared to Controls." The Journal of rheumatology vol. 49,1 (2022): 44-52. doi: https://doi.org/10.3899/jrheum.201470
Kiefer D, Baraliakos X, Adolf D, Chatzistefanidi V, Schwarze I, Lange U, Brandt-Jürgens J, Stemmler E, Sartingen S, Braun J. Successful Evaluation of Spinal Mobility Measurements With the Epionics SPINE Device in Patients With Axial Spondyloarthritis Compared to Controls. J Rheumatol. 2022 Jan;49(1):44-52. doi: 10.3899/jrheum.201470. Epub 2021 Aug 15. PMID: 34393107.
Copy Download .nbib Format: NLM
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.

Rheumatology and therapy

Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H.
PMID: 31254223
Rheumatol Ther. 2019 Sep;6(3):435-450. doi: 10.1007/s40744-019-0165-3. Epub 2019 Jun 28.

INTRODUCTION: Ixekizumab, a humanized interleukin-17A antibody, has shown efficacy in ankylosing spondylitis (AS), with a greater proportion of ixekizumab-treated patients achieving an ASAS40 (Assessment of Spondyloarthritis International Society 40) endpoint compared to placebo. An ASAS40 response is a high...

Cite
Mease P, Walsh JA, Baraliakos X, et al. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatol Ther. 2019;6(3):435-450doi: 10.1007/s40744-019-0165-3.
Mease, P., Walsh, J. A., Baraliakos, X., Inman, R., de Vlam, K., Wei, J. C., Hunter, T., Gallo, G., Sandoval, D., Zhao, F., Dong, Y., Bolce, R., & Marzo-Ortega, H. (2019). Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatology and therapy, 6(3), 435-450. https://doi.org/10.1007/s40744-019-0165-3
Mease, Philip, et al. "Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis." Rheumatology and therapy vol. 6,3 (2019): 435-450. doi: https://doi.org/10.1007/s40744-019-0165-3
Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatol Ther. 2019 Sep;6(3):435-450. doi: 10.1007/s40744-019-0165-3. Epub 2019 Jun 28. PMID: 31254223; PMCID: PMC6702662.
Copy Download .nbib Format: NLM
Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.

ACR open rheumatology

Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, Das Gupta A, Martin R, Safi J, Porter B, Shete A, Rosenbaum JT.
PMID: 32352653
ACR Open Rheumatol. 2020 May;2(5):294-299. doi: 10.1002/acr2.11139. Epub 2020 Apr 30.

OBJECTIVE: The objective of this study was to report the incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis (AS) in a pooled analysis of three phase 3 trials (MEASURE 1-3 [ClinicalTrials.gov identifiers NCT01358175, NCT01649375, NCT02008916]).METHODS: Analysis included pooled...

Cite
Deodhar AA, Miceli-Richard C, Baraliakos X, et al. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR Open Rheumatol. 2020;2(5):294-299doi: 10.1002/acr2.11139.
Deodhar, A. A., Miceli-Richard, C., Baraliakos, X., Marzo-Ortega, H., Gladman, D. D., Blanco, R., Das Gupta, A., Martin, R., Safi, J., Porter, B., Shete, A., & Rosenbaum, J. T. (2020). Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR open rheumatology, 2(5), 294-299. https://doi.org/10.1002/acr2.11139
Deodhar, Atul A, et al. "Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies." ACR open rheumatology vol. 2,5 (2020): 294-299. doi: https://doi.org/10.1002/acr2.11139
Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, Das Gupta A, Martin R, Safi J, Porter B, Shete A, Rosenbaum JT. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR Open Rheumatol. 2020 May;2(5):294-299. doi: 10.1002/acr2.11139. Epub 2020 Apr 30. PMID: 32352653; PMCID: PMC7231512.
Copy Download .nbib Format: NLM
Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon .

Annals of the rheumatic diseases

Baraliakos X, Gossec L, McInnes I, Kerschbaumer A, de Wit M, Dougados M, Primdahl J, van der Heijde D, Smolen JS.
PMID: 32963050
Ann Rheum Dis. 2020 Sep 22; doi: 10.1136/annrheumdis-2020-218676. Epub 2020 Sep 22.

No abstract available.

Cite
Baraliakos X, Gossec L, McInnes I, et al. Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218676.
Baraliakos, X., Gossec, L., McInnes, I., Kerschbaumer, A., de Wit, M., Dougados, M., Primdahl, J., van der Heijde, D., & Smolen, J. S. (2020). Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218676
Baraliakos, Xenofon, et al. "Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218676
Baraliakos X, Gossec L, McInnes I, Kerschbaumer A, de Wit M, Dougados M, Primdahl J, van der Heijde D, Smolen JS. Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon . Ann Rheum Dis. 2020 Sep 22; doi: 10.1136/annrheumdis-2020-218676. Epub 2020 Sep 22. PMID: 32963050.
Copy Download .nbib Format: NLM
Inhibition of Structural Joint Damage Progression with Upadacitinib in Rheumatoid Arthritis: 1-Year Outcomes from the SELECT Phase 3 Program.

Rheumatology (Oxford, England)

Peterfy CG, Strand V, Friedman A, Hall S, Mysler E, Durez P, Baraliakos X, Enejosa JV, Shaw T, Li Y, Chen S, Song IH.
PMID: 34897366
Rheumatology (Oxford). 2021 Dec 13; doi: 10.1093/rheumatology/keab861. Epub 2021 Dec 13.

OBJECTIVES: To evaluate the inhibition of progression of structural joint damage through week 48 in patients with moderately to severely active rheumatoid arthritis (RA) receiving upadacitinib as monotherapy or in combination with methotrexate.METHODS: Radiographic progression was assessed in two...

Cite
Peterfy CG, Strand V, Friedman A, et al. Inhibition of Structural Joint Damage Progression with Upadacitinib in Rheumatoid Arthritis: 1-Year Outcomes from the SELECT Phase 3 Program. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab861.
Peterfy, C. G., Strand, V., Friedman, A., Hall, S., Mysler, E., Durez, P., Baraliakos, X., Enejosa, J. V., Shaw, T., Li, Y., Chen, S., & Song, I. H. (2021). Inhibition of Structural Joint Damage Progression with Upadacitinib in Rheumatoid Arthritis: 1-Year Outcomes from the SELECT Phase 3 Program. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab861
Peterfy, Charles G, et al. "Inhibition of Structural Joint Damage Progression with Upadacitinib in Rheumatoid Arthritis: 1-Year Outcomes from the SELECT Phase 3 Program." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab861
Peterfy CG, Strand V, Friedman A, Hall S, Mysler E, Durez P, Baraliakos X, Enejosa JV, Shaw T, Li Y, Chen S, Song IH. Inhibition of Structural Joint Damage Progression with Upadacitinib in Rheumatoid Arthritis: 1-Year Outcomes from the SELECT Phase 3 Program. Rheumatology (Oxford). 2021 Dec 13; doi: 10.1093/rheumatology/keab861. Epub 2021 Dec 13. PMID: 34897366.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 77 entries